StockNews.AI
ALXO
StockNews.AI
182 days

ALX Oncology to Host Virtual R&D Day on March 5, 2025

1. ALX Oncology will host a virtual R&D Day on March 5, 2025. 2. The event will update on pipeline and lead candidate evorpacept. 3. Evorpacept is crucial for ALX's immuno-oncology therapy development. 4. Company focuses on boosting immune system to treat cancer. 5. Live webcast available with replays on ALX's website.

3m saved
Insight
Article

FAQ

Why Bullish?

The R&D Day highlights advancements in ALXO’s pipeline, particularly evorpacept. Similar past announcements have positively influenced stock prices of biotech firms.

How important is it?

This event is critical for investor perception and future financing. Successful updates can increase stock value reflecting market confidence.

Why Short Term?

The upcoming event could lead to immediate investor interest and stock movement. Previous biotech R&D events often result in short-term volatility.

Related Companies

ALXOBMYMRNANVDA
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, today announced that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET. The virtual webcast event will focus on information and updates related to the company’s pipeline, lead investigational CD47-blocker evorpacept, as well as business and financial updates. R&D Day Webcast InformationThe ALX Oncology virtual R&D Day will be webcast live and a replay will be available after the event by visiting the “Investors” section of ALX Oncology’s website and selecting “Events and Presentations.”  Date & Time: Wednesday, March 5, 2025, 6:00 a.m. PT/9:00 a.m. ETWebcast Access: https://edge.media-server.com/mmc/p/yfucf8t5About ALX OncologyALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology. Investor Relations Contact:Elhan Webb, CFA, IR Consultantewebb@alxoncology.com Media Contact: Audra Friis, Sam Brown, Inc.audrafriis@sambrown.com (917) 519-9577

Related News